Over a lifetime, 1 out of 7 men will receive a diagnosis of prostate cancer. Although most patients present with localized or indolent disease, there are still a big proportion of patients that will eventually progress to metastatic prostate cancer, for which no curative treatment currently ...
(177)Lu-PSMA radioligand therapy for prostate cancer Lu-177-prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) using inhibitors of PSMA is a novel therapeutic option in patients withmetastati... WP Fendler,K Rahbar,K Herrmann,... - 《Journal of Nuclear Medicine Official Publica...
Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources.
药物别名 177Lu-PSMA-617 药效学 Lutetium Lu 177 vipivotide tetraxetan is a radioligand that exerts cytotoxic effects on cancer cells. Tumor uptake value is 11.2%ID/g. In clinical trials of patients with metastatic castration-resistant prostate cancer, treatment with lutetium Lu 177 vipivotide te...
Shared insight from Rana McKay, MD, and the Oncology Brothers on updated data from PSMAfore and the use of Lutetium-177–PSMA-617 in patients with metastatic castration-resistant prostate cancer. EP: 1.SunRISe-1: Updated Data With TAR-200 Monotherapy in NMIBC ...
Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts...
If you have advanced prostate cancer, you know every day matters. PLUVICTO could give you more time for what's important to you and your loved ones. That's a victory. See How PLUVICTO May Help After hormone therapy and chemotherapy, ask about PLUVICTO. ...
Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body...
Dosimetric analysis of the short-ranged particle emitter 161Tb for radionuclide therapy of metastatic prostate cancer. Cancers. 2021;13:2011. Article CAS PubMed PubMed Central Google Scholar Bernhardt P, Benjegård SA, Kölby L, et al. Dosimetric comparison of radionuclides for therapy of ...
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate﹕pecific membrane antigen monoclonal antibody J591 ( 177 Lu㎎591) for metastatic castration‐resistant prostate cancerJaspreet S. Batra M.D. aMuhammad Junaid Niaz M.D. a